BTVA®

BRONCHOSCOPIC THERMAL VAPOR ABLATION

The InterVapor® System



Uptake Medical®

A Broncus Company

Bronchoscopic Thermal Vapor Ablation (BTVA®) treatment included in the 2020 GOLD Guidelines

Uptake Medical®
A Broncus Company

The Uptake Medical InterVapor® System is intended for treatment of patients with heterogeneous upper lobe emphysema to achieve bronchoscopic lung volume reduction by the application of heated water vapor to the most diseased lung segment(s) targeted for treatment.

The InterVapor IP3® treatment plan identifies the most diseased hyperinflated segments, and the dose of vapor to deliver, for optimal volume reduction.





(1)

*Baseline *6 Month Post Treatment

The InterVapor® System is designed to reduce the volume and mass of the most diseased and hyperinflated segments of the lung, allowing the healthier segments to expand. This approach allows multiple treatments over time to maximize patient benefit.

Primary endpoint efficacy measures at 6 months and 12 months after vapour ablation (2)



BTVA®:

- √ No risk of implant complications
- √ Vapor delivery time between 3 and 10 seconds
- √ Pneumothorax risk mitigated by gradual volume reduction
- √ Effective in CV+ and CV- patients (3)
- √ Compatible with 2.8mm working channel



ORDERING INFORMATION

Order Number UM-CTH-100 includes:
InterVapor Catheter
Personalized Procedure Program
Drain Bag: UM-BAG-100

CONTACT INFORMATION

info@uptakemedical.com or
contact your local representative

www.uptakemedical.com

Uptake Medical®
A Broncus Company

(1) Radiographic image of treated (in red) and preserved (in green) segments for a STEP-UP patient
(2) Shah, P. L., et al The Lancet Respiratory Medicine, 2016, http://dx.doi.org/10.1016/S2213-2600(16)30199-0
(3) Gompelmann, et al Respiration 2016;92:397–403, DOI: 10.1159/000452424